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LIFETIME DISTRIBUTION OF MEDICAL COST IN KOREA
Jung YH, Ko S
Korea Institute for Health and Social Affairs, Seoul, South Korea
OBJECTIVES: It has been well recognized that health-care cost is strongly dependent 
on age. The study aims at estimating the magnitude and distribution of lifetime medical 
costs. METHODS: We employ a period life table model using single year’s medical 
expenditures from Korea National Health Insurance Corporation, population data 
and life table from Korean Statistical Agency. To estimate lifetime medical costs for 
male and female, 100,000 hypothetical cohorts for each sex whose mortality rate 
coming from life table is constructed and assigned to medical costs at each age and 
sex. This procedure permits us to estimate lifetime medical costs at each age and for 
each sex. The method used here is to conceptually convert cross-sectional costs data 
into a longitudinal pattern of costs, which generates proﬁ les of medical cost from birth 
to death. RESULTS: The average member of the birth cohort will spend 74,150 
thousands Won (98,883 PPP US$) for man and 87,868 thousands Won (117,177 PPP 
US$) for woman in 2007 over the course of his or her life. Total lifetime medical cost 
is 19 percent higher for females than males due to mainly life expectancy difference. 
For the average life table member, half of all lifetime cost occurs after about age 65. 
We also estimate the distribution of lifetime medical cost by phases of life course. For 
a male (female), 12.7 (9.2) percent of a cohort’s expenditures occurs from birth to 
age 19; 8.4 (10.0) percent accrues during ages 20~39; 30.2 (28.4) percent is expended 
during ages 40~64; 42.7 (44.0%) percent is realized during ages 65~84; 5.9(8.4) 
percent accrues over age 85. CONCLUSIONS: The ﬁ ndings of this study are similar 
to the patterns of medical costs of other countries’ experiences provided by other 
literatures—high during infancy, low during childhood and young adulthood, then 
rising during middle-age and rapidly growing during the senior years. 
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THE COST OF ILLNESS IN KOREA (2007)
Jung YH
Korea Institute for Health and Social Affairs, Seoul, South Korea
OBJECTIVES: Illness is associated with signiﬁ cant economic burden on both indi-
vidual and society. This study aims at measuring the cost of illness in Korea in 2007. 
METHODS: We estimate both direct and indirect costs of illness using a prevalence-
based approach. Direct cost includes medical expenditures (inpatient, outpatient), 
caregiver’s cost and trafﬁ c costs. As indirect costs, productivity loss representing lost 
workdays due to illness and lost earnings due to premature death is estimated based 
on human capital theory. The results are reported according to age, sex, diseases and 
each cost items in USA Purchasing Power Parity (PPP) Dollars at 3% discount rate. 
The major data sources are National Health Insurance Statistical Yearbook, Annual 
Report on the Cause of Death Statistics, and Survey Report on Wage Structure. We 
also use other information such as the Korean Statistical Information System. We 
provide the results according to age, sex, and diseases at each cost items. RESULTS: 
The cost of illness of Korea in 2007 is 56,633,552 million Won (75,523 million PPP 
US$) based on 3% discount rate, which represents approximately 6.28% of GDP. Of 
this total, 47.8% (36,065 million PPP US$) is devoted to medical costs, followed by 
productivity loss (46.4%; 35,053 million PPP US$), caregiver’s costs (3.9%; 2,962 
million PPP US$), and transportation cost (1.9%; 1,444 million PPP US$). The cost 
of illness is higher for males (45,912 million PPP US$) than females (29,611 million 
PPP US$), which results from the difference of productivity loss cost. However, direct 
cost of females is higher than that of males. We ﬁ nd that the cost of aged 40~49 
accounts for the highest proportion (23.5%) followed by aged 50~59 (22.5%). The 
four major diseases incurring highest costs are as follows; neoplasms (18.76%), cir-
culatory system (13.92%), digestive system (13.55%), and respiratory system 
(10.53%). CONCLUSIONS: This study could provide basic information for establish-
ing prioritizations of health policies to reduce economic burden of illness and enhance 
quality of life. 
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TRENDS IN DRUG EXPENDITURES IN SONGKHLA HOSPITAL
Kultavayporn S, Saowapark P
Songkhla Hospital, Songkhla, Thailand
OBJECTIVES: To assess situations and trends in overall drug expenditures and to 
understand factors inﬂ uencing drug expenditures in Songkhla hospital. METHODS: 
It was across-sectional descriptive design research. Drug expenditures of ﬁ scal year 
2005–2007 at Songkhla hospital were studied. Overall drug purchase expenditures as 
well as their proportions including in the National drug list 2007 were ﬁ gured out. 
The expenses of drug subgroups and drug items were ranked and sorted from highest 
to lowest expenditures, compared with the previous 3 years. The study also presented 
the cost impact of the use of new drugs available in the ﬁ scal 3 years. The cost-savings 
of all generic drugs instead of original drugs were estimated. RESULTS: Total drug 
expenditure grew by 46.17% from 2005 to 2006 and grew by 43.03 % from 2006 
to 2007. And analysis of 17 drug groups and all drug items in terms of expenditure 
indicated that 1) the expenditure of top three groups in the ﬁ scal year 2004 and 2006 
was the same group (cardiovascular, infections, endocrine system), and the expendi-
ture of top three groups (cardiovascular, infections, central nervous system) about 
116.48 million baht, in the ﬁ scal year 2007; and 2) the expenditure of top 30 drug 
items (from about 612,651,677 items) was about 38.4, 69.18, 103.64 million baht, 
accounted for 36.52 %, 44.63%, and 41.42% of over all drug expense in the ﬁ scal 
year 2005–2007. CONCLUSIONS: The study indicated that forecasting and manag-
ing of rising drug expenditure remained a challenge for hospital administrators. The 
dynamic reimbursement environment would further complicated drug budgeting, and 
policy-makers of the hospital must consider factors affecting drug expenditures as 
well. 
PHP21
WHAT ARE THE TOP MOST COSTLY DISEASES FOR USA? THE 
ALIGNMENT OF BURDEN OF ILLNESS WITH PREVENTION AND 
SCREENING EXPENDITURES
Kockaya G1, Wertheimer A2
1Istanbul University Istanbul Medical Faculty, Istanbul, Turkey; 2Temple University School of 
Pharmacy, Philadelphia, PA, USA
OBJECTIVES: It was the intention of the authors to generate a list of the top diseases 
responsible for the greatest ﬁ nancial expense in the United States. This listing would 
then inform policymakers as to the highest priority target conditions. With such 
information available, funding for the NIH could be accomplished based upon factual 
criteria rather than political clout or uninformed consensus. METHODS: The ﬁ rst 
step was a literature review to explore articles and reports which were published about 
the cost of illness (COI) up to December 2009. Therefore the source of the data used 
in this investigation was obtained from this retrospective search approach. RESULTS: 
With reference to total cost for disease, ﬁ rst was HCVD with US$475.3 billion, fol-
lowed by alcohol abuse and substance at US$300.6 billion, digestive diseases at 
US$259.6 billion, cancer at US$239.5 billion and mental disease at US$216.6 billion. 
CONCLUSIONS: As has been seen, the total societal costs of the diseases do not 
synch with the degree of attention paid to these various disease states. Several of the 
diseases have very powerful and vocal support organizations that encourage attention 
and clinical research support. On the other hand we hear very little about efforts 
against allergic rhinitis or infectious and parasitic diseases. 
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UNIT COST OF BURMESE TRANSLATOR ACTIVITIES IN PHARMACY 
DEPARTMENT, SAMUTSAKHON HOSPITAL
Angkoonsit D
Samutsakhon Hospital, Mahachai, Thailand
OBJECTIVES: Burmese laborers are major Non-Thai patients in Samutsakhon Hos-
pital. Culture and language barriers between Samutsakhon Pharmacist and Burmese 
patients may lead to many drug related problems that effect to patients safety. For 
this reasons, Burmese transalators were worked like pharmacists assistants since May 
2008. This activity may improve quality of service as increased cost. This research is 
aim to determine labor cost of Burmese translators at pharmacy department, Samut-
sakhon Hospital. METHODS: This research is descriptive study in health-care pro-
vider prospective to determine labor cost of Burmese translators between October 1, 
2009 to December 31, 2009. Unit cost of Burmese translator was calculated from 
labor cost multiply with estimated time in each translator activities by observation. 
RESULTS: The results of this study found that labor cost of Burmese translator is 
0.98 bath/min, and unit cost of each activity included translating drug information 
for general patients costs 2.45 bath/case,while, dispensing vitamins for Burmese 
pregnancies which costs about 0.98 bath/case. Although giving drug information for 
TB and AIDs patients is 4.9 bath/case or translating the evaluating adverse drug reac-
tion is 9.8 bath/case. The most expensive cost is teaching to use special device for 
asthmatic patients about 14.7 bath/case. There are other assignments, for example, 
preparing Burmese drug leaﬂ ets or prepack medicines. Every activities are under 
responsibed by Thai pharmacists. CONCLUSIONS: From this study is quite similar 
to labor cost of Nurse assistants at Ledsin Hospital, Bangkok in 2005 (0.81 bath/min). 
Also, this information can be applied for other hospitals that in the similar situation. 
This study can help decision-maker to spend more budget to improve quality of 
pharmaceutical care with humanity. 
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HEALTH DECENTRALIZATION, GOVERNMENT HEALTH EXPENDITURE 
AND HEALTH OUTCOME IN CHINA
Chen Q, Li L
Peking University, Beijing, China
OBJECTIVES: Since the early 1980s, decentralization has reemerged as a valued politi-
cal and economic goal in most developing countries. China’s health-care system is also 
in the process of decentralization, local governments take more responsibilities of health 
sector, accompanied by the diminution of public role in health ﬁ nancing especially after 
the ﬁ scal reform in 1994. This research looks at the health outcome (both the level and 
gradient) during the period 1991–2007 to identify the effects of these policy changes on 
health outcomes in China. METHODS: we borrow the micro Grossman health produc-
tion model using province-level pooled cross-section and time-series data during the 
period 1991–2007. We ﬁ rst investigates the “overall” and “partial” effect of income on 
health, and then focus on the policy effects. Life expectancy, infant mortality, mortality, 
and maternal mortality are examined as health variables (level, gradient, and conver-
gence). Medical care, public health, socioeconomic, environmental factors as well as 
institutional variables are considered in the production function. RESULTS: The results 
are coincident with theoretical expectation i.e., economic growth alone does not 
promote health in typical developing countries, but some channels like its impact on 
public health do, and also the system does matter. The decentralization of government 
responsibilities and reduction of public role are signiﬁ cant for the fall of mortality and 
infant mortality and both signiﬁ cantly affect the sigma and beta convergence of health 
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variables. CONCLUSIONS: Economic development is important support for health 
development, but economic growth will not naturally improve health especially for the 
government investment on health. Rational incentives for the government is essential 
for health development. 
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VALIDATION OF ELECTRONIC DATABASE IN COMMUNITY HOSPITALS 
IN PATIENTS WITH ATRIAL FIBRILLATION
Chotchaisuwatana S1, Jedsadayanmata A2, Chaiyakunapruk N2, Jampachaisri K1
1Naresuan University, Muang, Phitsanulok, Thailand; 2Naresuan University, Muang, 
Phitsanulok, Thailand
OBJECTIVES: The electronic databases (ED) has been increasing used for clinical 
research since it reﬂ ects a routine care with large and heterogeneous samples. 
However, few studies report on its validity for such purposes, especially the ED from 
community hospitals. This study aims to assess the validity of EDs based on data from 
patients with atrial ﬁ brillation (AF) receiving care from community hospitals in Phit-
sanulok. METHODS: The validity of ED was determined using out-patient medical 
records (OPMRs) as a gold standard. A total of 200 AF patients were randomly 
sampled from a pool of patients with ICD-10 of AF (I48) from two community 
hospitals during August 2007–July 2008. For each patient, data of a randomly selected 
visit from the ED was matched to data of the same visit from OPMRs, abstracted by 
a standardized data collection form. The ED was cross-validated with OPMRs based 
on patient’s comorbidities (risk factors for stroke) and bleeding events. All data were 
tabulated in a 2 × 2 format to calculate sensitivity, speciﬁ city and the Cohen’s Kappa 
adjusted for chance agreement. RESULTS: Out of 200 AF patients, 176 were docu-
mented as having diagnosis of AF in OPMRs (88%). The ED data on risk factors of 
stroke showed moderate to high sensitivity (range 66.67–100%) and high speciﬁ city 
(range 99.36–100%). These results suggest that the risk factors of stroke were coded 
accurately. Based on these data, the agreement between two databases was considered 
good to very good (calculated kappa range 0.7940–0.9680). The speciﬁ city based on 
major bleeding was 100%; however, sensitivity and the Cohen’s Kappa could not be 
determined because the major bleeding diagnosis was found neither in the EMRs nor 
the OPMRs. CONCLUSIONS: The electronic database of AF patients from com-
munity hospitals was valid and in good agreement with the OPMRs. 
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USING COLLABORATIVE PROGRAM BETWEEN PHARMACISTS AND 
NURSES YO IMPROVE SPONTANEOUS ADVERSE DRUG REACTION 
REPORTING SYSTEM IN THAILAND
Prakongsai N1, Pongchaidecha M2
1Prapokklao Regional Hospital, Ministry of Public Health, Chantaburi province, Thailand; 
2Silpakorn University, Nakorn Pathom Province, Thailand
OBJECTIVES: To evaluate the collaborative program between pharmacists and nurses 
in improving the spontaneous reporting system (SRS) of ADR in Prapokklao hospital, 
and to explore the impact of the collaborative program on nurses’ knowledge about 
ADRs, capacity in detecting and reporting ADRs, and the level of satisfaction. 
METHODS: Several methods including experimental approach which categorized 
nurses into experimental and control groups, then compared knowledge before and 
after a training program and performance in detecting and reporting ADRs between 
both groups. Eight out of 52 nurses in the experimental group were intensively trained 
with knowledge about ADRs, and how to report ADRs in hospitalized patients. The 
rest (44 nurses) in the experimental group obtained knowledge from researchers and 
the training nurses. Nurses in both experimental and control groups were assessed 
about knowledge before and after the start of the program, performance in monitoring 
and reporting ADRs compared to pharmacists, and satisfaction using a self-adminis-
tered questionnaire. RESULTS: Eight nurses trained by the program and 44 nurses in 
the experimental group had a signiﬁ cant higher score of knowledge than before train-
ing. Differences in the pre and post-test scores between experimental and control 
groups were statistically signiﬁ cant at 0.05. Intensive ADR monitoring indicated that 
experimental wards had 3572 patients with 371 ADR problems, while control wards 
had 3467 patients with 266 problems. Nurses in the experimental groups could cor-
rectly report 174 ADR problems (46.9%), while 29 problems (10.9%) were reported 
by their counterparts. The difference in the capability to reporting ADR was at the 
signiﬁ cance level of 0.05. The level of probability and the difference in the proportion 
of ADR reported by the experimental group was fourfold to the control group. 
CONCLUSIONS: This collaborative program between pharmacists and nurses signiﬁ -
cantly improved performance and knowledge of nurse in SRS reporting system in 
Prapokklao hospital. 
PHP28
IMPACT OF SAFETY ISSUES’ BASED DECISIONS OF CONSULTATIVE 
COUNCIL ON THE POLISH NATIONAL HEALTH FUND’S BUDGET
Farkowski MM, Baran J, Matusewicz W
Agency for Health Technology Assessment in Poland, Warsaw, Poland
OBJECTIVES: Nowadays growing number of new health technologies entering 
market together with more aggressive therapies administered by physicians lead to 
increase in number and cost of care of related adverse effects (AE). We were interested 
in the impact of costs of AE related to medicines not recommended for public funding 
by the Consultative Council (CC) of Polish Heath Technology Assessment Agency 
(AHTAPol) on the ground of safety issues on the Polish National Health Fund’s 
budget. METHODS: Among decisions of CC published until the end of 2009, we 
distinguished those where safety issues were signiﬁ cant arguments for decline, and 
analyzed submissioned budget impact analyses (BIA) of those medicines in order to 
ﬁ nd the incremental costs of AE related to the treatment. Then, we compared those 
costs to the total incremental costs of public funding reported by manufacturers. 
RESULTS: Among 148 CC’s decisions analyzed, 70 were negative and in 22 safety 
issues were signiﬁ cant arguments against the positive recommendation (31% of all 
negative decisions). Out of 22 analyzed BIA’s only in two cases (10%) incremental 
costs of AE were explicitly stated, both medicines being used in oncology. In one case 
(4.5%), a reason for absence of those costs was stated. Stated incremental cost of AE 
of those two medicines was about 0.25 to 0.35 million USD in years 1 to 3 of public 
funding, which corresponds to about 2.5% of total incremental cost of those medicines 
and only 0.2% of total incremental costs of all 22 submissions (about 110 to 135 
million USD). CONCLUSIONS: In submissions rejected by CC where one of the 
main concerns were safety issues, manufacturers failed to explicitly show the impact 
of costs of adverse effects of their drugs on Polish National Health Fund’s 
budget. 
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ASSESSMENT OF THE ORPHAN DRUG PRICING AND REIMBURSEMENT 
LANDSCAPE IN THE ASIA PACIFIC REGION
Mukku SR1, Pang F2
1Double Helix Consulting, London, UK; 2Shire Human Genetic Therapies, Basingstoke, UK
OBJECTIVES: In recent years, there has been a steady increase in products for chronic 
rare diseases. The aim of this research is to assess the current pricing and reimburse-
ment framework for orphan and ultra-orphan drugs - identifying emerging trends, 
deﬁ ning the key components of health technology assessments, observing government 
and payer policies, and reviewing previous access decisions in relation to the Asia-
Paciﬁ c region. METHODS: Interviews were conducted with a variety of stakeholders 
(payers, academics, KOLs) to identify the key determinants inﬂ uencing the pricing and 
reimbursement and access strategies of orphan drugs in AP countries including Aus-
tralia, China, Japan, India, Singapore, South Korea. These were supported by in-depth 
secondary analyses from government websites, the WHO, reports and OECD statis-
tics. RESULTS: Decisions reviewed for a selection of drugs (e.g., Naglazyme, Glivec, 
Tracleer) across a number of therapeutic areas in the context of indicators including 
population size, price level, %GDP on health care (Singapore 3.4%, India 4.9%, 
China 4.5%, Australia 9.1%), number of specialists etc, inferred that there is signiﬁ -
cant variability in uptake. Orphan deﬁ nitions vary by country from 4/10,000 in Japan 
to 1.2/10,000 in Australia. Pricing, payment and regulation mechanisms also differ 
across countries including ﬁ nancial incentives, protocol assistance, fast-track proce-
dures and market exclusivity (Years: US = 7, EU = 10, Japan = 10, Australia = none). 
Nearly 100 orphan drugs have been approved over the past 12 years in Japan. In 
predominantly self-pay markets such as China and India, many orphan diseases 
remain untreated. Policy determinants include economic troubles impacting health-
care budgets, stakeholder attempts to rationalize investment, population demographic 
shifts, affordability, desire for consistency across and within markets and the require-
ment to contain rising health-care costs while respecting the philosophy of the health-
care system (egalitarian vs.ulitarian). CONCLUSIONS: Health system and payer 
attitudes toward health provision are evolving over time, impacting the type of 
approach taken to address orphan and ultra-orphan product access in the Asia-Paciﬁ c 
region. 
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MARKET ACCESS, AFFORDABILITY AND PRICE COMPONENTS OF 
MEDICINES IN THE UNITED ARAB EMIRATES (UAE)
Ansary A1, Abuelkhair M2, Mukku S3
1University of Cambridge, Cambridge, UK; 2Health Authority-Abu Dhabi, Abu Dhabi, United 
Arab Emirates; 3Double Helix Consulting, London, UK
OBJECTIVES: The research was aimed at understanding the complexities of pricing 
and reimbursement practices in UAE with analysis focussing on price mark-ups, 
affordability, stakeholder analysis and strategic recommendations for pharmaceutical 
companies to launch products in this market. METHODS: Interviews were conducted 
with Payers and KOLs to understand patient ﬂ ow, health-care issues and drug pricing 
in UAE. In addition in-depth secondary analysis was conducted. RESULTS: UAE with 
a population of 4.2 million has seen more than 700% growth from 1975–2006, 
contributed mostly by expatriate work force. This has signiﬁ cantly impacted on the 
management of health care in recent years. Medicines priced in the UAE are generally 
high because of the lack of pharmaceuticals manufacturing base and subsequent reli-
ance on imports. While individuals spend $52 in the gulf countries and $20 in other 
Arab countries on medicines, an individual in the UAE spends about $80 a year. There 
is a markup of up to 20% and 24% by the wholesalers and retail pharmacies, respec-
tively; which is relatively high in comparison to many other countries resulting in 
expensive drugs that become unaffordable. A lack of competition legislation and anti-
competitive practices means that pharmacies in the UAE are required to buy medicines 
solely through few agents who hold exclusive rights to importing and distributing 
products. Also there are differences among the UAE regions; e.g., HAAD is introduc-
ing additional controls through a differential co-payments and reference pricing when 
insufﬁ cient competition is observed. As part of market access policy development, the 
UAE MoH has started applying basic pharmaco-economic methodologies that consid-
ers the active ingredient’s strength, dosage, and therapeutic effect. CONCLUSIONS: 
The pricing and reimbursement policy in its current form is not-sustainable. New 
pricing models need to be considered in order to ensure a healthy population with 
good access to affordable medicines and health care in the UAE. 
